Alopecia

Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Alopecia Clinical Trials Review

Alopecia Clinical Trials Review

Global Alopecia Clinical Trials Review

The “Alopecia – Global Clinical Trials Review, H2, 2021” clinical trials have been added to the ResearchAndMarkets offering.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs for in-progress trials (based on a number of ongoing trials).

The report enhances the decision-making capabilities and helps to create an effective counter-strategies to gain a competitive advantage.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with the reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Key Topics Covered:

  • Report Guidance
  • The Publisher’s Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Alopecia to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Alopecia Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profile Snapshots
  • Appendix

Companies Mentioned

  • Pfizer Inc
  • Concert Pharmaceuticals Inc
  • Johnson & Johnson
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Cosmo Pharmaceuticals NV
  • Dr. Reddy’s Laboratories Ltd
  • Almirall SA
  • Applied Biology Inc
  • GlaxoSmithKline Plc

For more information about this clinical trials report visit https://www.researchandmarkets.com

Global Alopecia Clinical Trials Review

Source

Recent Posts

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment market exposition comprehensive information that help to build business strategists during the forecast 2021-2027.

Which provides an exhaustive analysis of key market trends & dynamics along with market estimates & forecasts covering major geographies/countries on the basis of historical data. Considering Platelet Rich Plasma and Stem Cell Alopecia Treatment revolutions of the cat1 industry which is major factors of growth.

Research Methodology

Our research methodology constitutes a mix of secondary & primary research sources which ideally starts from exhaustive data mining, conducting primary interviews (suppliers/distributors/end-users), and formulating insights, estimates, growth rates accordingly. Final primary validation is a mandate to confirm our research findings with Key Opinion Leaders (KoLs), Industry Experts, Self-Adhesive Labels includes major supplies & Independent Consultants among others.

The report used two methodologies FPNV Positioning Matrix and the Competitive Strategic Window to assess the figures for all segments and competitive marketplace in terms of product satisfaction and business strategy they follow to sustain in the market.

Pharmaceuticals and Healthcare Development

– India has reached out to top American pharma companies seeking investment in the country’s pharmaceutical and medical devices sector
– The Serum Institute of India will invest 240 million pounds in the UK
– The annual change in WPI notified by the government works out to 0.5% for 2020, the drug prices regulator National Pharmaceutical Pricing Authority said.

Market Segmentation

The Platelet Rich Plasma and Stem Cell Alopecia Treatment market is segmented on the basis of type, application, end-use industry, and region & country.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Type

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment type, the market is divided into type Androgenic Alopecia, Congenital Alopecia, Cicatricial Or Scarring Alopecia. Platelet Rich Plasma and Stem Cell Alopecia Treatment market’s sub-segment is expected to hold the largest market share during the forecast period. Increased demand for high-quality industrial valves in the Pharmaceuticals and Healthcare and other industries.

Also to mitigate the risk of contamination is driving the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment at present. The growing concern about the market and industry is expected to boost the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in Pharmaceuticals and Healthcare.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market by Application

Based on Platelet Rich Plasma and Stem Cell Alopecia Treatment application, the market is divided into Hospital, Dermatology Clinic, Other. Platelet Rich Plasma and Stem Cell Alopecia Treatment application valves are one of the most basic and indispensable components of today’s modern technological society. A market segment is expected to hold the largest market share in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market.

Global Market Scope and Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size

The scope of the report is to provide a 360-degree view of the market by assessing the entire value chain and analyzing the key Platelet Rich Plasma and Stem Cell Alopecia Treatment market trends from 2021 to 2027 underlying in specific geographies. Qualitative and quantitative aspects are interlinked to provide rationales on market numbers, CAGR, and forecasts.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Country Level Analysis

Most of the countries are estimated to emerge as the fastest growing region and hold the largest market share in the global industrial Platelet Rich Plasma and Stem Cell Alopecia Treatment market, mainly due to Growing industry trends of present situations, which cannot be ignored. Geographically, regional insights have been segmented on the basis of North America, Europe, Asia Pacific, South America and The Middle East And Africa region.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment market players identified in the report are listed below

Kerastem, Stemcell Technologies, Eclipse, Glofinn Oy., Regen Lab SA, Histogen, RepliCel Life Sciences

Market

Some of the other major highlights of the demand for Platelet Rich Plasma and Stem Cell Alopecia Treatment report include analysis, purchasing volume, prices, pricing analysis, and regulatory framework. Coverage on manufacturing structure, distribution channels, and Porter’s Five Forces analysis are also incorporated in the scope to provide analysis on the demand and supply side. This is anticipated to create opportunities for the growth of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market during the forecast period.

COVID-19 Impact Analysis

– The COVID-19 pandemic had a significant impact on the on-trade segment and Industry.
– Manufacturers are comprehending strategies to revive from the current situation by means of reshaping their sales channels as well as product innovation.
– The duration of the virus outbreak remains a key factor in assessing the overall impact of the pandemic. However, the global Platelet Rich Plasma and Stem Cell Alopecia Treatment industry is expected to stabilize after 2021.
– The liquor industry was not impacted severely due to the pandemic.

Key Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Trends

– The report identifies, determines, and forecasts the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market segments based on their type, sub-type, technology used, applications, end-users, and regions.
– Industry to Industry Holds Largest Share in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market
– It examines the micro-markets based on their growth trends, development patterns, future prospects, and contribution to the overall market.
– Demand from Regional / geographical is Expected to Drive the Growth
– Rising Adoption of Market Segments in the Platelet Rich Plasma and Stem Cell Alopecia Treatment Growth
– North American, Europe is Expected to Witness Higher Growth Rate over the Forecast Period
– It studies the competitive developments such as partnerships and collaborations, mergers and acquisitions (M&A), research and development (R&D) activities, product developments, and expansions in the Global Platelet

Rich Plasma and Stem Cell Alopecia Treatment Market.

Table of Contents

Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market, years considered, and study objectives. Additionally, it touches on the segmentation study provided in the report on the basis of the type of product and application.

Executive Summary: It gives a summary of key studies, market growth rate, competitive landscape, market drivers, trends, and issues, and macroscopic indicators.

Production by Region: Here, the report provides information related to import and export, production, revenue, and key players of all regional markets studied.

Profile of Manufacturers: Each player profiled in this section is studied on the basis of SWOT analysis, their products, production, value, capacity, and other vital factors.

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Growth are segmented on the basis of market type, application, end-user and region.

Based on Type

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

Based on Application

Hospital
Dermatology Clinic
Other

Regions Covered

Americas
North America
United States
Canada
Mexico
South America
Brazil
Argentina
Chile
Colombia
Rest Of Latin America

Europe
United Kingdom
Germany
France
Italy
Spain
Netherlands
Sweden
Rest of Europe

Asia-Pacific
China
India
Japan
South Korea
Australia
Singapore
Indonesia
Malaysia
Thailand
Philippines,
Vietnam
Rest of Asia-Pacific

The Middle East And Africa
Saudi Arabia
United Arab Emirates
South Africa
Iran
Turkey
Morocco
Nigeria
Algeria
Cameroon
Chad
Congo
Egypt
Kuwait
Rest of LAMEA

Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

Source

Recent Posts

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Androgenic Alopecia Drug Market Size and Forecasts 2021 to 2027

The Global Androgenic Alopecia Drug Market witnessed a rapid growth in the historic period from 2016 to 2019 and is anticipated to witness significant growth during the forecast period.

Global Androgenic Alopecia Drug Market Size, Trends, Growth, Competitive Landscape and Key Regional Analysis to 2027” offers broad information and understanding of the Androgenic Alopecia Drug markets. The report analyses the Androgenic Alopecia Drug market for the historical (2016–2020) and forecast (2021–2027) periods. The report includes drivers, restraints and opportunities influencing the market, market size analysis with respect to revenue.

The report also provides a snapshot of the competitive landscape of the key players operating in the market along with the percentage market share of the top players. The report has a section on the impact of COVID-19 on the Androgenic Alopecia Drug market at the global and country levels.

This analysis includes demand & supply-side implications of the Androgenic Alopecia Drug market in 2019. The report is built using data and information sourced from primary & secondary research, proprietary databases paid database among others.

Androgenic Alopecia Drug Market Snapshot

Scope of the Androgenic Alopecia Drug Market Report:

This report provides an in-depth analysis of the Global Androgenic Alopecia Drug Market. The market estimates and forecasts provided in the research report are the results of in-depth secondary research coupled with primary interviews and in-house expert opinions. These market estimates and forecasts have been considered by reviewing the impact of various political, social, and economic factors along with the current market scenarios affecting the Androgenic Alopecia Drug market growth

Along with the Androgenic Alopecia Drug market summary, which includes the market dynamics comprising of drivers, restraints, and opportunities the chapter also includes a Porter’s Five Forces analysis which explains: the threat of new entrants, buyers bargaining power, bargaining power of supplier, the threat of substitutes, and competitive rivalry in the Global Androgenic Alopecia Drug Market. Furthermore, the supply chain analysis explains the various participants, such as raw material suppliers, system integrators, distributors, intermediaries and end-users within the ecosystem of the Androgenic Alopecia Drug market. It provides vendor landscape at the global level and summary of the key upcoming projects/ products

Segments Covered in the Androgenic Alopecia Drug Market Report:

This report forecasts revenue growth at global, regional, and country levels and offers an analysis of latest industry developments in each of the sub-segments from 2016 to 2027.

Global Androgenic Alopecia Drug Market, By Product

  • RK-023
  • Refagro
  • RCH-01
  • SM-04554
  • HYG-440
  • Others

Global Androgenic Alopecia Drug Market, By Application

  • Clinic
  • Hospital
  • Home Use

Androgenic Alopecia Drug Market Regional Overview:

The report offers in-depth analysis of the Androgenic Alopecia Drug market at the global, regional (North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa) and key country (the US, Canada, China, India, Japan, South Korea, the U.K., Germany, France, Brazil, Mexico) levels. The market estimates and forecasts for the segmentation mentioned in the study will be provided at regional and country level. The market estimates and forecast will help understand the dominant region in 2020 and will further enlighten the upcoming region that will generate major revenue in the Androgenic Alopecia Drug market.

Global Androgenic Alopecia Drug Market: Competitive Landscape

The market analysis includes a chapter solely dedicated for key players operating in the Global Androgenic Alopecia Drug Market wherein the analysis provide an insight of the business overview, financial statements, product overview, and the strategic initiatives adopted by the market players. The companies mentioned in the study can be customized according to the client’s requirements.

Global Androgenic Alopecia Drug Market, Key Players

  • Allergan, Inc.
  • Histogen, Inc.
  • R-Tech Ueno, Ltd.
  • Hygeia Therapeutics, Inc.
  • SWITCH Biotech LLC
  • Polichem S.A.
  • Kasiak Research Pvt. Ltd.

Key Questions Addressed:

  • Which innovative technology trends are expected over the next seven years?
  • Which sub segment is likely to get the maximum opportunity to grow during the forecast period?
  • Which region is projected to lead with the highest market share by 2027?
  • How are companies instigating organic and inorganic strategies to gain a surge in the market share?

Global Androgenic Alopecia Drug Market: Research Methodology

The research methodology is a mix of primary research, secondary research and industry opinion leaders. Moreover, secondary research comprises of sources such as company annual reports, press releases, and research papers related to the industry. Other sources include government websites, trade journals and associations are also been reviewed for developing business growth strategies in Androgenic Alopecia Drug Market.

Androgenic Alopecia Drug Market Size and Industry Analysis Report, by Type, by Application, by Country & Region, and Segment Forecasts, 2016 – 2027

Source

Recent Posts

Alopecia Areata- Market Insight

Alopecia Areata- Market Insight

Alopecia Areata- Market Insight, Epidemiology and Market Forecast -2030

Alopecia Areata Market

DelveInsight’s “Alopecia Areata – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Alopecia Areata, historical and forecasted epidemiology as well as the Alopecia Areata market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alopecia Areata market report provides current treatment practices, emerging drugs, Alopecia Areata market share of the individual therapies, current and forecasted Alopecia Areata market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Alopecia Areata treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Alopecia Areata Disease Understanding and Treatment Algorithm

The DelveInsight Alopecia Areata market report gives a thorough understanding of the Alopecia Areata by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Alopecia Areata.

Treatment

It covers the details of conventional and current medical therapies available in the Alopecia Areata market for the treatment of the condition. It also provides Alopecia Areata treatment algorithms and guidelines in the United States, Europe, and Japan.

Alopecia Areata Epidemiology 

The Alopecia Areata epidemiology division provides insights about historical and current Alopecia Areata patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides a historical as well as forecasted Alopecia Areata epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Alopecia Areata Epidemiology

The epidemiology segment also provides the Alopecia Areata epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Alopecia Areata Drug Chapters

The drug chapter segment of the Alopecia Areata report encloses the detailed analysis of Alopecia Areata marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Alopecia Areata clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Alopecia Areata treatment.

Alopecia Areata Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Alopecia Areata treatment.

Alopecia Areata Market Outlook

The Alopecia Areata market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Alopecia Areata market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.

This segment gives a thorough detail of Alopecia Areata market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alopecia Areata market in 7MM is expected to change in the study period 2017-2030.

Key Findings

This section includes a glimpse of the Alopecia Areata market in 7MM.

The United States Market Outlook

This section provides the total Alopecia Areata market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Alopecia Areata market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Alopecia Areata market size and market size by therapies in Japan is also mentioned.

Alopecia Areata Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Alopecia Areata market or expected to get launched in the market during the study period 2017-2030. The analysis covers Alopecia Areata market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alopecia Areata Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Alopecia Areata key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Alopecia Areata emerging therapies.

Reimbursement Scenario in Alopecia Areata

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME’s opinions working in the Alopecia Areata domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Alopecia Areata market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Alopecia Areata Market by using various Competitive Intelligence tools that include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Alopecia Areata, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Alopecia Areata epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Alopecia Areata is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Alopecia Areata market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alopecia Areata market

Report Highlights

  • In the coming years, the Alopecia Areata market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Alopecia Areata R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Alopecia Areata. The launch of emerging therapies will significantly impact the Alopecia Areata market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Alopecia Areata
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Alopecia Areata Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Alopecia Areata Pipeline Analysis
  • Alopecia Areata Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Alopecia Areata Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Alopecia Areata Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Alopecia Areata Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions

Market Insights:

  • What was the Alopecia Areata market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Alopecia Areata total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Alopecia Areata market size during the forecast period (2017-2030)?
  • At what CAGR, the Alopecia Areata market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Alopecia Areata market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Alopecia Areata market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Alopecia Areata?
  • What is the historical Alopecia Areata patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Alopecia Areata in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Alopecia Areata?
  • Out of all 7MM countries, which country would have the highest prevalent population of Alopecia Areata during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Alopecia Areata treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Alopecia Areata in the USA, Europe, and Japan?
  • What are the Alopecia Areata marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Alopecia Areata?
  • How many therapies are developed by each company for Alopecia Areata treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Alopecia Areata treatment?
  • What are the key collaborations (Industry – Industry, Industry – Academia), Mergers and acquisitions, licensing activities related to the Alopecia Areata therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Alopecia Areata and their status?
  • What are the key designations that have been granted for the emerging therapies for Alopecia Areata?
  • What are the global historical and forecasted market of Alopecia Areata?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Alopecia Areata market
  • To understand the future market competition in the Alopecia Areata market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Alopecia Areata in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Alopecia Areata market
  • To understand the future market competition in the Alopecia Areata market

Alopecia Areata- Market Insight, Epidemiology and Market Forecast -2030

Source

Recent Posts

Aesthetics Treatments for Body Improvement

Aesthetics Treatments for Body Improvement

ABM Launches Three Medical Procedures Aesthetics Treatments for Body Improvement

ABM Medical Clinic & Cosmetics, a top-rated clinic for body improvements and facial aesthetics, is proud to announce the addition of three new aesthetic medical procedures. The new body rejuvenation treatments include PRP (Platelet-Rich Plasma) Facial, PRP Therapy for Hair Loss, and Vampire Facial.

Our PRP Facial cosmetic procedure helps tighten the skin and quickens the healing process. Whether wrinkles, age spots, scarring, or hyperpigmentation, our team of board-certified physicians uses a minimally invasive treatment to remove scars, improve skin tone and texture, boost collagen and elastin, and rejuvenate the skin.

We combine both traditional micro needling and modern collagen induction therapy to improve effects and achieve faster results. Our PRP facial procedure is proven to be safe with no chance for allergic reactions because the plasma comes from your own body.

In addition, ABM Medical Clinic & Cosmetic is happy to introduce an innovative hair loss treatment.

Our PRP Hair Loss medical procedure is a product of years of consistently exploring the best options for hair loss solutions. This three-step medical hair restoration procedure uses PRP to trigger healthy hair growth in dying hair follicles.

It also increases the thickness of the hair shaft, helping you revitalize natural hair. Our hair restoration strategy is for women and men seeking the best alternative to hair transplant surgery by appropriately fixing hair loss.

We have also added a nonsurgical cosmetic procedure called Vampire Facial to help men and women offset ageing effects like hollowed-out skin, crow’s feet, bumps, and certain skin deformities. Our Vampire Facial clinical procedure uses cellular therapy to rejuvenate the skin and provide a youthful, natural, and healthy appearance without the need for plastic surgery. It is a non-invasive cosmetic procedure that requires only topical anaesthesia.

We are committed to providing you with the healthiest skin and body, keeping you in the best physical state regardless of age. For more information about our process and to book a free consultation:

ABM Launches Three Medical Procedures Aesthetics Treatments for Body Improvement

Source

Recent Posts

Genetic Test for Hair Loss

Genetic Test for Hair Loss

The First Genetic Test for Hair Loss: Introducing TrichoTest, from Fagron

Fagron North America, a global leader in pharmaceutical compounding, debuts the most advanced genetic test supporting medical practitioners’ assessment and treatment of hair loss in the US: TrichoTest.*

TrichoTest is a genetic test performed on patients’ DNA that analyzes 13 genes and 48 genetic variations related to alopecia, including androgenetic alopecia, alopecia areata, and telogen effluvium. This genetic test is based on state-of-the-art DNA microarray technology and utilizes a patented algorithm to provide a personalized treatment recommendation to medical practitioners from 175 million therapeutic alternatives.

TrichoTest analyzes prostaglandins metabolism, inflammation, androgenic effect, vasodilation and blood circulation, collagen synthesis, vitamins and minerals metabolism, and insulin-like growth factor metabolism.

Introducing the most advanced genetic test supporting assessment and treatment of hair loss: TrichoTest, by Fagron.

Alopecia is a progressive and multifactorial condition related to endogenous and exogenous factors. Often, endogenous factors are genetics and are associated with gene expression. The most common type of hair loss, known as androgenetic alopecia, is hereditary. If left untreated, hair loss usually progresses over time.

TrichoTest is the most complete genetic test for alopecia, analyzing genetic factors and other relevant patient characteristics.

TrichoTest supports treatment efficacy. The test results can help medical practitioners develop a personalized treatment plan for their patients, which may include compounded topical solutions, oral supplements, and prescription hair care products.

Today, TrichoTest is the only complete genetic test for alopecia and hereditary hair loss in the US market.

About Fagron North America
Fagron North America (NA), a top-tier pharmaceutical supplier, is focused on creating the future of personalized medicine through investments in genomics, technology, pharmacy essentials and 503B outsourcing.

Fagron Inc., a Fagron NA brand, produces high-quality, innovative pharmaceutical raw materials, equipment, and supplies to prepare personalized medication in the pharmacy. Fagron Inc. offers a broad product portfolio across oral and topical compounding ingredients. As a global leader in pharmaceutical compounding, Fagron supports patient-focused medication that works to improve quality of life.

*TrichoTest is not approved by the Food and Drug Administration and is not intended to diagnose, treat, cure or prevent disease. Any recommendations given to the requesting medical practitioner are for informational purposes only and no individual is required to use any products mentioned in a report.

The First Genetic Test for Hair Loss: Introducing TrichoTest, from Fagron

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia

Stem Cell and Platelet Rich Plasma Alopecia

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

The research team projects that the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market size will grow from XXX in 2020 to XXX by 2027, at an estimated CAGR of XX. The base year considered for the study is 2020, and the market size is projected from 2020 to 2027.

The prime objective of this report is to help the user understand the market in terms of its definition, segmentation, market potential, influential trends, and the challenges that the market is facing with 10 major regions and 50 major countries.

Deep researches and analysis were done during the preparation of the report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts.

The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

By Market Players:

Orange County Hair Restoration Center
Colorado Surgical Center & Hair Institute
Evolution Hair Loss Institute
Hair Sciences Center of Colorado
Hair Transplant Institute of Miami
Anderson Center for Hair
Virginia Surgical Center
Savola Aesthetic Dermatology Center

By Type

Platelet Rich Plasma Injections
Stem Cell Therapy

By Application

Dermatology Clinics
Hospitals

By Regions/Countries:

North America
United States
Canada
Mexico
East Asia
China
Japan
South Korea
Europe
Germany
United Kingdom
France
Italy
Russia
Spain
Netherlands
Switzerland
Poland
South Asia
India
Pakistan
Bangladesh
Southeast Asia
Indonesia
Thailand
Singapore
Malaysia
Philippines
Vietnam
Myanmar
Middle East
Turkey
Saudi Arabia
Iran
United Arab Emirates
Israel
Iraq
Qatar
Kuwait
Oman
Africa
Nigeria
South Africa
Egypt
Algeria
Morocoo
Oceania
Australia
New Zealand
South America
Brazil
Argentina
Colombia
Chile
Venezuela
Peru
Puerto Rico
Ecuador
Rest of the World
Kazakhstan

Points Covered in The Report

The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 12 years of data history and forecast.

The growth factors of the market is discussed in detail wherein the different end users of the market are explained in detail.

Data and information by market player, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have a comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and their impact on the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements.

The report focuses on Global, Top 10 Regions and Top 50 Countries Market Size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies 2016-2021, and development forecast 2022-2027 including industries, major players/suppliers worldwide and market share by regions, with the company and product introduction, position in the market including their market status and development trend by types and applications which will provide its price and profit status, and marketing status & market growth drivers and challenges, with the base year as 2020.

Key Indicators Analysed

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2021 & Sales by Product Types.

Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2022-2027. Further the report provides break down details about each region & countries covered in the report.

Identifying its production, consumption, import & export, sales volume & revenue forecast.

Market Analysis by Product Type: The report covers the majority of Product Types in the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry, including its product specifications by each key player, volume, sales by Volume and Value (M USD).

Market Analysis by Application Type: Based on the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Industry and its applications, the market is further sub-segmented into several major Applications of its industry. It provides you with the market size, CAGR & forecast by each industry application.

Market Trends: Market key trends include Increased Competition and Continuous Innovations.

Opportunities and Drivers: Identifying the Growing Demands and New Technology

Porters Five Force Analysis:

The report will provide the state of competition in the industry depends on five basic forces: the threat of new entrants, bargaining power of suppliers, bargaining power of buyers, the threat of substitute products or services, and existing industry rivalry.

COVID-19 Impact

The report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency.

The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market in 2021. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

2021-2027 Global and Regional Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Source

Recent Posts

CTP-543 THRIVE Clinical Program

CTP-543 THRIVE Clinical Program

The Patient Recruiting Agency, LLC Announces Enrollment Launched for the CTP-543 THRIVE Clinical Program Investigating Oral Treatment for Moderate to Severe Alopecia Areata

The Patient Recruiting Agency™ announces open enrollment for the THRIVE Clinical Program, a series of clinical trials exploring the investigational product CTP-543 for the potential oral treatment of moderate to severe alopecia areata. CTP-543 is being developed by Concert Pharmaceuticals, Inc.

The purpose of the ongoing THRIVE Clinical Program is to measure the effect of CTP-543 on hair regrowth and to evaluate safety in people with alopecia areata.

The THRIVE Clinical Program is now enrolling adults 18 to 65 years old with at least 50% scalp hair loss due to alopecia areata. The current episode of hair loss must have lasted at least 6 months and no longer than 10 years. The total time a person has had alopecia areata may exceed 10 years.

Following a 24-week treatment period, participants will have the opportunity to enrol into an open-label extension study in which all participants will receive an active dose of CTP-543.

The THRIVE Clinical Program is being conducted at multiple research study centres throughout the United States and Canada. For more information about this important clinical research study, please visit our study website.

CTP-543 is a selective Janus kinase (JAK) inhibitor intended to disrupt the process that causes hair follicles to be incorrectly targeted by the body’s immune system. There are currently no FDA-approved treatments for alopecia areata.

US Thrive Clinical Program Website: https://www.mythrivestudy.com

Canadian Thrive Clinical Program Website: https://www.mythrivestudy.ca

About The Patient Recruiting Agency™

Located in Austin, Texas, The Patient Recruiting Agency™ (TPRA) supports Sponsors, CROs, SMOs, and Investigators with patient recruitment services.

The Patient Recruiting Agency, LLC Announces Enrollment Launched for the CTP-543 THRIVE Clinical Program Investigating Oral Treatment for Moderate to Severe Alopecia Areata

Source

Recent Posts

Alopecia Treatment

Alopecia Treatment

Global Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2028

Alopecia treatment (hair loss) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the alopecia treatment (hair loss) market to account to USD 5,461.35 million by 2028 growing at a CAGR of 6.0% in the above-mentioned forecast period. Rising prevalence of alopecia (hair loss) globally and extensive research & development activity in alopecia treatment (hair loss) has been directly impacting the growth of alopecia treatment (hair loss) market.

Alopecia is a condition that causes hair to fall out in small patches, which can be unnoticeable. These patches may connect, however, and then become noticeable. The condition develops when the immune system attacks the hair follicles, resulting in hair loss.

Increasing need for effective treatment for alopecia (hair loss) is the main driving factor for the alopecia treatment (hair loss) market. Rising pharmaceutical industries and various research & clinical studies is driving the alopecia treatment (hair loss) market. Various innovative clinical programmes is an opportunity for the alopecia treatment (hair loss) market.

Lack of awareness in rural countries is a big challenge for the alopecia treatment (hair loss) market. However, high cost of treatment is the main restraint in the growth of alopecia treatment (hair loss) market during the forecast period of 2021-2028.

This alopecia treatment (hair loss) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

In March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical to improve the sales of its product which is Rogaine, a hair loss treatment including minoxidil. JW Pharmaceutical has signed a distributorship agreement with J&J in November 2017. Rogaine is FDA approved hair loss treatment and is considered a top-selling hair loss treatment. This lead enabled the company to gain more product sales which have increased the company’s overall revenue.

Alopecia Treatment (Hair Loss) Market Scope and Market Size

Alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on disease type, the alopecia treatment (hair loss) market is segmented into non‒cicatricial alopecia, cicatricial alopecia, traction alopecia and others.
  • Based on treatment, the alopecia treatment (hair loss) market is segmented into localized therapies, systemic therapies, medical devices and herbal treatment.
  • Based on gender, the alopecia treatment (hair loss) market is segmented into male and female.
  • Based on form, the alopecia treatment (hair loss) market is segmented into oral, topical and parenteral.
  • Based on end user, the alopecia treatment (hair loss) market is segmented into hospitals, home healthcare and dermatology centers.
  • Based distribution channel, the alopecia treatment (hair loss) market is segmented into direct tender, retail sales and pharmacies.

Alopecia Treatment (Hair Loss) Market Country Level Analysis

Alopecia treatment (hair loss) market is segmented into is analysed and market size insights and trends are provided by country, disease type, treatment, gender, form, end user and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market is segmented into report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is likely to lead the alopecia treatment (hair loss) market. The regional market has been driven by common form of alopecia and people with alopecia aerate affects. However, growing market with new players is the main factor propelling the growth of the regional market. The market in Asia-Pacific is expected to exhibit a substantial growth rate during the forecast period 2021-2028 due to rise in prevalence of alopecia and rising usage of hair care therapies for the treatment.

The country section of the alopecia treatment (hair loss) market is segmented into report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for alopecia treatment (hair loss) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the alopecia treatment (hair loss) market. The data is available for historic period 2010 to 2019.

Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis

Alopecia treatment (hair loss) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to alopecia treatment (hair loss) market.

The major players covered in the alopecia treatment (hair loss) market report are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Par Pharmaceutical, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., Aurobindo Pharma, Perrigo Company plc, Viviscal Limited, Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech are among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Alopecia Treatment (Hair Loss) Market – Industry Trends and Forecast to 2028

Source

Recent Posts

Study in Alopecia Areata

Study in Alopecia Areata

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

Concert Pharmaceuticals, Inc today will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss.

The data show that relative to the previous Phase 2 study results of CTP-543, hair regrowth assessed by the Severity of Alopecia Tool (SALT) was maintained or improved in the great majority of patients through one year of continuous dosing with 12 mg twice-daily of CTP-543. Approximately 57% of participants receiving 12 mg of CTP-543 twice-daily following 52 weeks of dosing achieved a clinically meaningful SALT score of 20 or less. Dosing in the long-term extension study is ongoing, and patients completing the ongoing Phase 3 THRIVE-AA trials are eligible to enrol in the study. These data will

“With its Breakthrough Therapy designation, we are excited about the prospect of CTP-543 for the treatment of alopecia areata as we advance it through its Phase 3 clinical program.

Through the Phase 3 program and long-term extension study we are building a robust body of data to support our New Drug Application with the FDA, which we plan to file in early 2023,” said James V. Cassella, PhD, Concert’s Chief Development Officer, who made the oral presentation at the Summit. “We are committed to understanding how alopecia areata affects the whole person and are working diligently to advance CTP-543 as one of the first FDA-approved therapies for this serious autoimmune condition.”

“We believe Janus kinase inhibitors, or JAKs, are an important mechanism in the treatment of autoimmune disorders, including alopecia areata,” said Maryanne Senna, MD, principal investigator of the Hair Academic Innovative Research Unit at Massachusetts General Hospital. “Through clinical research, we are at a point where we better understand the utility of this class of medicines and believe for the first time that new treatments could be on the horizon.”

CTP-543 has been generally well-tolerated in the long-term extension study with only 4 of the 158 subjects entering the study discontinuing due to adverse events to date. Adverse events are consistent with those previously reported in the Phase 2 trials. Clinical labs for key haematology parameters appear stable across the long-term extension study relative to the end of treatment in the Phase 2 trials.

Details from the oral presentation, entitled “Update on Long-Term Safety & Efficacy of CTP-543, an Oral JAK Inhibitor, for the Potential Treatment of Alopecia Areata” will be available at 11:55 a.m. ET in the Scientific Presentations section of Concert’s website in connection with the meeting presentation.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect approximately 1 million Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

About Concert

Concert Pharmaceuticals is a clinical-stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

Source

Recent Posts